Literature DB >> 11054516

The effect of waiting for radiotherapy for grade III/IV gliomas.

V Do1, V Gebski, M B Barton.   

Abstract

AIM: To determine the effect of waiting time for radiotherapy on the overall survival of patients with high-grade gliomas.
METHODS: We examined records of patients with grade III/IV gliomas who were referred to radiotherapy after surgery or biopsy - ECOG <3, any age, radical intent or palliative intent with dose >50 Gy, no interstitial or radiosurgery boost. Waiting time was defined in two ways, time from biopsy to radiotherapy and time from presentation to radiotherapy department to start of radiotherapy.
RESULTS: There were 182 patients in the study having a median survival of 8.5 months, with a median follow up of 10.5 months. The group comprised of 63 (35%) grade III and 119 (65%) grade IV gliomas. Median times and ranges from biopsy and presentation to treatment were 26 days (4-78 days) and 15 days (1-62 days), respectively. The median dose was 60 Gy in a median of 30 fractions over a median of 46 days. Tumour progression before and during radiotherapy occurred in seven patients (4%) and 19 patients (11%), respectively. One hundred and seventy-nine patients died of disease. The seven patients whose tumour progressed before radiotherapy were excluded from the analysis of prognostic variables. In a multivariate analysis the variables that were significantly associated with worse survival were older age, reduced dose and prolonged waiting time from presentation. The risk of death increased by 2% for each day of waiting for radiotherapy.
CONCLUSION: The study showed longer waiting time from presentation at radiotherapy department to treatment to be a significant predictor of overall survival for patients with high-grade glioma.

Entities:  

Mesh:

Year:  2000        PMID: 11054516     DOI: 10.1016/s0167-8140(00)00257-7

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  42 in total

1.  Waiting times before initiation of radiotherapy might not affect outcomes for patients with glioblastoma: a French retrospective analysis of patients treated in the era of concomitant temozolomide and radiotherapy.

Authors:  Georges Noel; Aymeri Huchet; Loic Feuvret; Jean Philippe Maire; Pierre Verrelle; Emilie Le Rhun; Maud Aumont; François Thillays; Marie Pierre Sunyach; Chantal Henzen; Fernand Missohou; Renaud de Crevoisier; Pierre Yves Bondiau; Philippe Collin; Xavier Durando; Gilles Truc; Christine Kerr; Valérie Bernier; Jean-Baptiste Clavier; David Atlani; Anne D'Hombres; Sandrine Vinchon-Petit; Jean Léon Lagrange; Luc Taillandier
Journal:  J Neurooncol       Date:  2012-06-02       Impact factor: 4.130

Review 2.  Delayed initiation of radiotherapy for glioblastoma: how important is it to push to the front (or the back) of the line?

Authors:  Yaacov Richard Lawrence; Deborah T Blumenthal; Diana Matceyevsky; Andrew A Kanner; Felix Bokstein; Benjamin W Corn
Journal:  J Neurooncol       Date:  2011-04-24       Impact factor: 4.130

3.  Temporal changes in magnetic resonance imaging characteristics of Gliadel wafers and of the adjacent brain parenchyma.

Authors:  Stephan Ulmer; Klara Spalek; Arya Nabavi; Susan Schultka; H Maximillian Mehdorn; Santosh Kesari; Lutz Dörner
Journal:  Neuro Oncol       Date:  2012-02-08       Impact factor: 12.300

4.  Super-early initiation of temozolomide prolongs the survival of glioblastoma patients without gross-total resection: a retrospective cohort study.

Authors:  Haihui Jiang; Wei Zeng; Xiaohui Ren; Yong Cui; Mingxiao Li; Kaiyuan Yang; Mohammad Elbaroody; Song Lin
Journal:  J Neurooncol       Date:  2019-06-07       Impact factor: 4.130

5.  Early initiation of chemoradiation following index craniotomy is associated with decreased survival in high-grade glioma.

Authors:  Jay K Nathan; Amanda L Brezzell; Michelle M Kim; Denise Leung; D Andrew Wilkinson; Shawn L Hervey-Jumper
Journal:  J Neurooncol       Date:  2017-07-25       Impact factor: 4.130

6.  The Effect of Timing of Concurrent Chemoradiation in Patients With Newly Diagnosed Glioblastoma.

Authors:  Seunggu J Han; W Caleb Rutledge; Annette M Molinaro; Susan M Chang; Jennifer L Clarke; Michael D Prados; Jennie W Taylor; Mitchel S Berger; Nicholas A Butowski
Journal:  Neurosurgery       Date:  2015-08       Impact factor: 4.654

7.  Delay in radiotherapy shortens survival in patients with high grade glioma.

Authors:  Chris Irwin; Martin Hunn; Gordon Purdie; David Hamilton
Journal:  J Neurooncol       Date:  2007-06-20       Impact factor: 4.130

8.  Clinical course of high-grade glioma patients with a "biopsy-only" surgical approach: a need for individualised treatment.

Authors:  C Balaña; J Capellades; P Teixidor; I Roussos; R Ballester; M Cuello; A Arellano; R Florensa; R Rosell
Journal:  Clin Transl Oncol       Date:  2007-12       Impact factor: 3.405

9.  Temporal relationship of post-operative radiotherapy with temozolomide and oncologic outcome for glioblastoma.

Authors:  Daniel E Spratt; Michael Folkert; Zachary S Zumsteg; Timothy A Chan; Kathryn Beal; Philip H Gutin; Elena Pentsova; Yoshiya Yamada
Journal:  J Neurooncol       Date:  2013-11-05       Impact factor: 4.130

10.  Effectiveness of temozolomide for primary glioblastoma multiforme in routine clinical practice.

Authors:  J A B van Genugten; P Leffers; B G Baumert; H Tjon-A-Fat; A Twijnstra
Journal:  J Neurooncol       Date:  2009-07-07       Impact factor: 4.130

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.